Immunotherapy for the treatment of multiple myeloma
New endpoints in clinical trials to better serve patients
Elihu H. Estey
Can we cure 50% of all multiple myeloma patients in the next five years?
Current therapy for CLL and the new monoclonal antibody ofatumumab
The pros and cons of MRI and PET-CT for assessing response in multiple myeloma